ICBII UPDATE ON THE ROAD TO THE CURE Common Link Between Parkinson’s, Alzheimer’s and SchizophreniaCategory: Road to the Cure
Common Link Between Parkinson’s, Alzheimer’s and Schizophrenia
This article focuses on a potential common link related to the dysfunctional synaptic plasticity that science associates with neurodegenerative disorders such as Parkinson’s, Alzheimer’s, and schizophrenia. A specific protein implicated in the cognitive decline of Alzheimer’s also appears to play a role in the genetic predisposition to Parkinson’s and Schizophrenia, meaning that a drug that targets that protein could potentially treat a variety of neuropsychiatric disorders, according to a new study published October 18, 2018, in the Journal of Molecular Psychiatry.
This protein is known as Striatal-Enriched Protein Tyrosine Phosphatase (STEP) and plays an important role in the healthy functioning of synapses, the connections between brain cells. Excessive amounts of STEP protein are found in the brains of humans and animal models of Alzheimer’s disease, Parkinson’s disease, fragile X syndrome, and schizophrenia. The increase in STEP leads to a disruption of synaptic function and contributes to the cognitive deficits present in these disorders.
An experimental drug designed to inhibit the STEP protein restores cognitive deficits in a mouse model of Alzheimer’s disease. The researchers have shown that genetically eliminating STEP or using the drug to inhibit STEP activity improves cognitive deficits in a mouse model that has behavioral features related to symptoms of Schizophrenia. Unfortunately, these small molecule drugs stop working after a while as is the case with L-Dopa.
These findings suggest that a STEP inhibitor if developed, may be the basis of a new drug that can treat any number of neurodegenerative diseases.
ICB International, Inc. has the technology to develop inhibitors of STEP protein. The Company plans to start a research program to develop STEP-SMART Molecule to restore cognition of Alzheimer’s, Parkinson’s, and schizophrenia patients and provide these patients a chance to live a normal life.
WOULD YOU LIKE TO HELP get their drugs to market faster? The joy of being a part of this historical event can be had by helping ICBII find the funds to bring these trials to fruition through your investing, and by finding others with the financial ability and humanitarian mindset to accomplish the, until now, impossible. Please contact Jo Rosen at 760-773-5628 or JoRosen@Parkinsonsresource.org or by contacting ICBII directly through their website icbii.com/ or by phone 858-455-9880.
IMAGINE the world without Parkinson’s, MSA or Alzheimer’s disease. JUST IMAGINE.